Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin...

Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin despite a nearly 12-fold increase over year-ago levels. Revenue for the three months ended March 31 totaled $144,100, up from $11,250 during the same quarter last year but still lagging the analyst consensus by more than 76%, as a sizeable chunk of the quarters revenue from Melafind sales were deferred.
Comments (3)
  • jerflo
    , contributor
    Comments (5) | Send Message
    what would it take for this device to catch on
    1 May 2013, 04:03 PM Reply Like
  • nick159
    , contributor
    Comments (83) | Send Message
    This device will catch on because anyone who knows anything about skin cancer knows that a prospective skin cancer patient would rather have a noninvasive test first rather than being cut with a scalpel for a biopsy.
    1 May 2013, 04:48 PM Reply Like
  • sndnagy
    , contributor
    Comment (1) | Send Message
    If a dermatologist says it is negative and MelaFind says it is negative, then nothing more need be done. But if either one says it is positive, then I want a biopsy. All MelaFind needs to do to succeed is for it to indeed prove to be right when the dermatologist says nothing to worry about. If that doesn't happen, then you can use the stock for wallpaper.
    2 May 2013, 01:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs